Pulmonx Corporation (LUNG)
$1.76-2.22%Close
SELLRECOVERY · day 3
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $74M
- Beta
- 0.28
- P/E (TTM)
- -1.53
- Short % float
- 2.17%
- Days to cover
- 3.2
- SI change
- -5.3%
- 1W
- -1.12%
- 1M
- -10.66%
- vs SPY 1W
- -0.98%
- vs SPY 1M
- -13.17%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 8
- VALUE
- 8
- GROWTH
- 40
- GARP
- 4
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-58.0%
REV YoY-
ROE-96.7%
EPS YoY-
ROA-41.9%
GROSS77
OP-53
NET-55
[VALUATION]
P/E TTM-1.53
P/E FWD-
SECTOR PE20.34
INDUSTRY PE22.66
P/B1.89
P/FCF-
EV/EBITDA-1.74
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E143.41
ALTMAN Z-
CURR RATIO4.32
ND/EBITDA-
BETA0.28
Company news
FAQ
- What is LOPJLB’s current signal on LUNG?
- LOPJLB’s latest quantitative signal on Pulmonx Corporation (LUNG) is SELL in a RECOVERY regime. Signals are updated daily.
- What market regime is LUNG in?
- Pulmonx Corporation (LUNG) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does Pulmonx Corporation (LUNG) do?
- Pulmonx Corporation is a biomedical technology firm dedicated to developing and commercializing advanced, less invasive devices for managing chronic obstructive pulmonary diseases. Its primary offering, the Zephyr Endobronchial Valve, is specifically engineered to treat bronchoscopic hyperinflation in adults afflicted with severe emphysema. Complementing its therapeutic solutions, the company a…